Antiplatelet Therapy, Pretreatment, and Primary PCI: Every Minute Counts.

Competing Interests: Funding Support and Author Disclosures Dr Silvain has received research grants/consultant fees/lectures fees from AstraZeneca, Bayer HealthCare SAS, Abbott Medical France SAS, Biotronik, Boehringer Ingelheim France, CSL Behring SA, Gilead Science, Sanofi France, Terumo France SAS, and Zoll; and is a stockholder of 4P-Pharma. Dr Montalescot has received research grants/consultant fees/lectures fees from Abbott, Amgen, AstraZeneca, Axis, Bayer, Bristol Myers Squibb, Boehringer Ingelheim, Boston Scientific, Cell Prothera, CSL Behring, Idorsia, Leo-Pharma, Lilly, Medtronic, Novartis, Pfizer, Quantum Genomics, Sanofi, and Terumo. Dr Guedeney has reported that he has no relationships relevant to the contents of this paper to disclose.